Clinical Trials Logo

Biomarker clinical trials

View clinical trials related to Biomarker.

Filter by:

NCT ID: NCT03812627 Completed - Biomarker Clinical Trials

Study of Systemic Impact of Trace Elements Release by Implantable Medical Devices. Identification of Biomarkers of Systemic Inflammation

PROMETOX
Start date: June 24, 2019
Phase: N/A
Study type: Interventional

The main objective of this study is to evaluate the systemic impact of salting out of trace elements (TE) by metallic and nonmetallic implantable medical devices (IMD) and in particular the immune response of the organism to these trace elements and of their target organs, and to identify circulating protein biomarkers which might indicate an evolution of inflammation caused by an IMD.

NCT ID: NCT03532711 Completed - Clinical trials for Metastatic Colorectal Cancer

Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer

Start date: January 1, 2012
Phase:
Study type: Observational

Chemoresistance remains an obstacle in treating people with metastatic colorectal cancer (mCRC). Studying samples of blood and tumor tissue in the laboratory from patients with mCRC receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers. It may also help doctors predict how patients will respond to treatment. In this study, we aimed to evaluate biomarkers in chemotherapy regimens for first-line chemotherapy for mCRC.

NCT ID: NCT03469765 Completed - Acute Kidney Injury Clinical Trials

(TIMP-2)x(IGFPB7) to Predict Acute Kidney Injury (AKI) in Aortic Surgery

TIGER
Start date: June 19, 2018
Phase:
Study type: Observational

New biomarkers that predict the development of renal dysfunction in patients with aortic surgery are urgently needed. The investigators investigate whether urinary (TIMP-2)x(IGFBP7) predicts postoperative Acute Kidney Injury and/or need for Renal Replacement Therapy (RRT) in patients after aortic surgery (including EVAR).

NCT ID: NCT03164798 Completed - Stroke Clinical Trials

Serum BDNF Role as a Biomarker for Stroke Rehabilitation

BDNF
Start date: February 1, 2017
Phase:
Study type: Observational

This study aims to develop the quantitative biomarker to establish the individualized strategy in stroke rehabilitation. Brain-derived neurotrophic factor (BDNF) acts on certain neurons of the central nervous system (CNS) helping to support the survival of existing neurons, and encourage the growth and differentiation of new neurons and synapses. BDNF in CNS can be assessed by analysing serum BDNF. The final objective of this study is to demonstrate a role of biomarker of BDNF in stroke rehabilitation to establish the individualized strategy.

NCT ID: NCT03066310 Completed - Bladder Cancer Clinical Trials

Urine-DNA Biomarkers in Detecting Bladder Cancer

Start date: January 17, 2017
Phase:
Study type: Observational

DNA biomarkers in urine are important diagnostic and prognostic indicators for bladder cancer. Many genetic alterations have been identified in the urinary DNA. However, not all bladder tumors harbor mutations in the most commonly altered oncogenes. Thus, to reach satisfactory sensitivity and specificity a new diagnostic test should include multiple biomarkers. The investigators will conduct a prospective evaluation of a panel of mutations in urine-DNA test for the detection of urothelial bladder carcinoma in patients with gross hematuria for cystoscope.

NCT ID: NCT01239914 Completed - Clinical trials for Coronary Artery Disease

CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)

COACT
Start date: January 2005
Phase:
Study type: Observational

COACT registry is a multicenter registry of consecutive patients undergoing coronary stent implantation at 8 centers in the Catholic University of Korea to evaluate the real world management of patients with coronary artery disease and to assess their in-hospital, medium and long-term outcomes.

NCT ID: NCT01159730 Completed - Biomarker Clinical Trials

Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of multiple doses of VB-201 administered for 4 weeks and its efficacy on biomarkers.